äÇÑ±Ô ¸íÀÇ

¾ÈÀüÇÑ ÃÖ¼Òħ½À ¿ä·Î°á¼®¼ö¼ú Àü¹®ÀÇ

äÇÑ±Ô ¸íÀÇ

  • ¼Ò ¼Ó
    °­µ¿¼º½Éº´¿ø ºñ´¢±â°ú
  • Àü¹®ºÐ¾ß
    ¿ä·Î°á¼®, ½ÅÀå°á¼®, ¿ä°ü°á¼®, Àü¸³¼±ºñ´ëÁõ

äÇÑ±Ô ±³¼ö´Â ¿ä·Î°á¼®°ú Àü¸³¼± ÁúȯÀ» Áß½ÉÀ¸·Î ÃÖ¼Òħ½À ³»½Ã°æ ¼ö¼úÀ» Àü¹®ÀûÀ¸·Î ½ÃÇàÇϰí ÀÖÀ¸¸ç, ȯÀÚÀÇ ½ÅüÀû ºÎ´ãÀ» ÁÙÀ̸鼭µµ ³ôÀº Ä¡·á È¿°ú¸¦ ¾ò´Â Áø·á¸¦ ¸ñÇ¥·Î Çϰí ÀÖ´Ù. ƯÈ÷ Ãֽг»½Ã°æ Àåºñ¿Í °ü·ù¡¤ÈíÀÎ ½Ã½ºÅÛÀ» Ȱ¿ëÇÑ ¾ÈÀüÇÑ °á¼®¼ö¼ú(RIRS¡¤UMP µî)¿¡ °­Á¡À» °¡Áö°í ÀÖÀ¸¸ç, º¹ÀâÇÑ °á¼®À̳ª Àç¹ß¼º °á¼® ȯÀÚ¿¡¼­µµ ü°èÀûÀÎ Áø´Ü°ú ¸ÂÃãÇü Ä¡·á Àü·«À» Á¦½ÃÇÑ´Ù. ÇÐȸ Ȱµ¿°ú ¿¬±¸¿¡µµ Àû±ØÀûÀ̸ç, ³»½Ã°æ ¼ö¼úÀÇ ¾ÈÀü¼ºÀ» ³ôÀ̱â À§ÇÑ ¿¬±¸¸¦ ¼öÇàÇØ ±¹³»¿Ü Çмú¹«´ë¿¡¼­ Ȱ¹ßÈ÷ ¹ßÇ¥Çϰí ÀÖ´Ù. ȯÀÚ¿ÍÀÇ ¼ÒÅëÀ» Áß½ÃÇϸç, ¡°ºÎ´ãÀº ÁÙÀ̰í Ä¡·áÀÇ Á¤È®µµ´Â ³ôÀδ١±´Â öÇÐÀ¸·Î Áø·áÇÑ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °è¸í´ë ÀÇ´ë Çлç
  • ¿ï»ê´ë ÀÇ´ë ¼®»ç
  • ¿ï»ê´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) ÇѸ²´ëÇб³ °­µ¿¼º½Éº´¿ø ÀÓ»óÁ¶±³¼ö
  • ¿ï»ê´ëÇб³ Àǰú´ëÇÐ °­¸ª¾Æ»êº´¿ø Á¶±³¼ö (2020 ~ 2023)
  • ¼­¿ï¾Æ»êº´¿ø ºñ´¢ÀÇÇаú Àü°øÀÇ/ÀÓ»ó°­»ç (2015 ~ 2019)

¼ö»ó³»¿ª

Awards List
  • ´ëÇѼö¼ú°¨¿°ÇÐȸ Çмú´ëȸ ÃÖ¿ì¼ö Æ÷½ºÅÍ»ó (2017)
  • ´ëÇѺñ´¢ÀÇÇÐȸ Á¤±âÇмú´ëȸ ±¹¿Ü³í¹® ÀÓ»ó ÃÖ¿ì¼ö»ó (2022)

ÇÐȸȰµ¿

Academic activities
  • 2023 ~ ÇöÀç´ëÇѺñ´¢³»½Ã°æ·Îº¿ÇÐȸ ÇмúÀ§¿ø
  • 2023 ~ ÇöÀç´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ÀÌ»ç
  • 2025 ~ ÇöÀç´ëÇѺñ´¢ÀÇÇÐȸ ÆíÁýÀ§¿ø/»çȸ°øÇåÀ§¿ø/ºñ´¢³»½Ã°æÀÎÁõÀ§¿ø
  • 2025 ~ ÇöÀç´ëÇѺñ´¢³»½Ã°æ·Îº¿ÇÐȸ ÀÌ»ç/¿¬±¸À§¿ø/±³À°À§¿ø/ÆíÁýÀ§¿ø/¿ä·Î°á¼®´ë»çÀ§¿ø
½ÅÀå ÃÊÀ½ÆÄ °Ë»ç¿Í ½ÅÀå Á¶Á÷°Ë»ç 1ÆÇ
´ëÇ¥¼­Àû

½ÅÀå ÃÊÀ½ÆÄ °Ë»ç¿Í ½ÅÀå Á¶Á÷°Ë»ç 1ÆÇ

  • ÀúÀÚ(±Û)¼Û»óÈÆ ¿Ü
  • ÃâÆÇ»ç´ëÇѺñ´¢ÃÊÀ½ÆÄÇÐȸ
  • ¹ßÇàÀÏ2022³â 5¿ù 29ÀÏ
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 1°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 6°Ç
Á¦ ¸ñ Comparison of the Efficacy Between the Single-Dose and Three-Day Prophylactic Antibiotic Regimens for the Prevention of Bacterial Infections in Patients with Percutaneous Nephrolithotomy: A Randomized Controlled Study
¹ßÇ¥³âµµ 2018 ¹ßÇ¥Áö Urogenital Tract Infection
Á¦ ¸ñ Efficacy and Safety of Human Bone Marrow-Derived Mesenchymal Stem Cells According to Injection Route and Dose in a Chronic Kidney Disease Rat Model
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö International Journal of Stem Cells
Á¦ ¸ñ Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Frontiers Immunology
Á¦ ¸ñ Effect of perioperative tamsulosin on successful ureteral access sheath placement and stent-related symptom relief: A double-blinded, randomized, placebo-controlled study
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Frontiers Immunology
Á¦ ¸ñ Characteristics of Kidney Stones that Lead to High Stone-Free Rates in Supine Ultra-Mini Percutaneous Nephrolithotomy
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Archivos Españoles de Urología
Á¦ ¸ñ Comparative Trends in the Treatment of Male Lower Urinary Tract Symptoms in South Korea and the United States of America (USA) Based on Korean National Health Insurance Data
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö World Journal of Mens Health

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

¿ä·Î°á¼®ÀÇ ÃÖ¼Òħ½À ³»½Ã°æ ¼ö¼úÀ» ÁÖµÈ ºÐ¾ß·Î Çϸç, Ãֽаü·ù¡¤ÈíÀÎ ½Ã½ºÅÛÀ» Ȱ¿ëÇÑ ¾ÈÀüÇÑ °á¼®Ä¡·á¿¡ °­Á¡À» °®°í ÀÖ´Ù. º¹ÀâÇÑ °á¼® ȯÀÚÀÇ ¸ÂÃãÇü Ä¡·á¿Í ¼ú±â Ç¥ÁØÈ­¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, °ü·Ã ±â¼úÀ» ÁÖÁ¦·Î ÇÑ ±¹Ã¥°úÁ¦¸¦ ¼öÇàÇÏ¸ç ±¹³»¿Ü Çмú¹«´ë¿¡¼­µµ Ȱ¹ßÈ÷ ¿¬±¸¼º°ú¸¦ ¹ßÇ¥Çϰí ÀÖ´Ù.

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

ȯÀÚÀÇ ºÒÆí°ú ºÎ´ãÀ» ÃÖ¼ÒÈ­Çϸ鼭µµ ¾ÈÀüÇϰí Á¤È®ÇÑ Ä¡·á¸¦ Á¦°øÇÏ´Â °ÍÀ» °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÕ´Ï´Ù. Áø´ÜºÎÅÍ Ä¡·á, ¼ö¼ú ÈÄ È¸º¹±îÁö ¸ðµç °úÁ¤¿¡¼­ ȯÀÚ¿Í ÃæºÐÈ÷ ¼ÒÅëÇϸç, °¢°¢ÀÇ »óȲ¿¡ ¸Â´Â ÃÖ¼±ÀÇ Ä¡·á Àü·«À» Á¦½ÃÇÏ´Â °ÍÀ» Áø·áÀÇ ÇÙ½É °¡Ä¡·Î µÎ°í ÀÖ½À´Ï´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

ºñ´¢±â ÁúȯÀº Á¤¹ÐÇÑ Áø´Ü°ú ÀûÀýÇÑ ½Ã±â¿¡ ÀÌ·ç¾îÁö´Â Ä¡·á°¡ ¹«¾ùº¸´Ù Áß¿äÇÕ´Ï´Ù. ÃֽŠÃÖ¼Òħ½À ±â¼ú°ú Ç¥ÁØÈ­µÈ ¼ú±â¸¦ ¹ÙÅÁÀ¸·Î, ȯÀÚºÐÀÇ »óÅ¿¡ °¡Àå ÀûÇÕÇÑ Ä¡·á Àü·«À» Á¦½ÃÇØµå¸®°íÀÚ ÇÕ´Ï´Ù. Á¤È®ÇÏ°í ¾ÈÀüÇÑ Áø·á·Î ÃÖ¼±ÀÇ °á°ú¸¦ µå¸®°Ú½À´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°­µ¿¼º½Éº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1588-4100
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°­µ¿¼º½Éº´¿øÀº 1986³â °³¿øÇÑ Á¾ÇÕ ÀÇ·á±â°üÀÌ´Ù µÎ°æºÎ¾Ï, ³ú•½ÉÀåÇ÷°üÁúȯ, ¼ÒÈ­±âÁúȯ µî ÁßÁõ Áúȯ Ä¡·á¸¦ Àü¹®À¸·Î Çϰí ÀÖÀ¸¸ç µÎ°æºÎ¾Ï¼¾ÅÍ, ½ÉÀåÇ÷°ü¼¾ÅÍ, ¼ÒÈ­±âº´¼¾ÅÍ, Àå±âÀ̽ļ¾ÅÍ, ÇÏÀ̺긮µå¼ö¼ú¼¾ÅÍ µî 8°³ ¼¾ÅÍÈ­ üÁ¦¸¦ ±¸ÃàÇØ Áúȯ Áß½ÉÀÇ ÁýÁßÀûÀÎ Ä¡·á¸¦ ÇÑ´Ù. ÇÏÀ̺긮µå¼ö¼ú¼¾ÅÍ¿¡¼­´Â ÷´Ü ¿µ»óÀåºñ¸¦ ÀÌ¿ëÇØ ȯÀÚÀÇ »óŸ¦ Áø´ÜÇÏ°í ±× ÀÚ¸®¿¡¼­ Ç÷°ü ÁßÀç½Ã¼ú°ú ¿Ü°úÀû ¼ö¼úÀ» µ¿½Ã¿¡ ½ÃÇàÇÑ´Ù.

°­µ¿¼º½Éº´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã °­µ¿±¸ ¼º¾È·Î 150

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä